• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Rabbit anti-Human MEK2 Polyclonal Antibody

The antibody against MEK2 was raised in Rabbit using a synthetic peptide corresponding to a sequence within amino acids 1-100 of human MEK2 (NP_109587.1) as the immunogen. The polyclonal antibody exists as a isotype IgG, by affinity purification. This antibody has been validated on WB, IHC-P, IF/ICC, ELISA.

ADA-13175A

The antibody against MEK2 was raised in Rabbit using a synthetic peptide corresponding to a sequence within amino acids 1-100 of human MEK2 (NP_109587.1) as the immunogen. The polyclonal antibody exists as a isotype IgG, by affinity purification. This antibody has been validated on WB, IHC-P, IF/ICC, ELISA.

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ADA-13175A ClonalityPolyclonal
Host SpeciesRabbitTarget NameMEK2
Target SynonymsCFC4; MEK2; MKK2; MAPKK2; PRKMK2; K2FormLiquid
Species ReactivityHuman, Mouse, RatIsotypeIgG
Storage Buffer50% Glycerol, PBS with 0.01% thimerosal, pH7.3.Purification MethodAffinity purification
Positive SamplesHeLa, 293T, HT-29ApplicationELISA, WB, IF/ICC, IHC-P

Immunogen Information


Immunogen DescriptionA synthetic peptide corresponding to a sequence within amino acids 1-100 of human MEK2 (NP_109587.1).Target SpeciesHuman
Immunogen SequenceMLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARUniprot IDP36507
Background Information
  • Uniprot Id

    P36507

  • Target Species

    Human

  • Target Name

    MAP2K2

  • Target Full Name

    Dual specificity mitogen-activated protein kinase kinase 2

  • Target Function

    Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases. Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation.

  • Target Involvement

    Cardiofaciocutaneous syndrome 4 (CFC4)

  • Target Subcellular Location

    Cytoplasm. Membrane; Peripheral membrane protein.

  • Target Protein Families

    Protein kinase superfamily, STE Ser/Thr protein kinase family, MAP kinase kinase subfamily

  • Target Synonyms

    Cardiofaciocutaneous syndrome; CFC syndrome; CFC4; Dual specificity mitogen activated protein kinase kinase 2; Dual specificity mitogen-activated protein kinase kinase 2; ERK activator kinase 2; FLJ26075; MAP kinase kinase 2; map2k2; MAPK / ERK kinase 2; MAPK/ERK kinase 2; MAPKK 2; MAPKK2; MEK 2; MEK2; Microtubule associated protein kinase kinase 2; Mitogen activated protein kinase kinase 2; Mitogen activated protein kinase kinase 2 p45; MKK 2; MKK2; MP2K2_HUMAN; OTTHUMP00000165826; OTTHUMP00000165827; PRKMK 2; PRKMK2

  • Target Background

    The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in this gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, cognitive disability, and distinctive facial features similar to those found in Noonan syndrome. The inhibition or degradation of this kinase is also found to be involved in the pathogenesis of Yersinia and anthrax. A pseudogene, which is located on chromosome 7, has been identified for this gene.

Inquire Rabbit anti-Human MEK2 Polyclonal Antibody Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification